Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study

BACKGROUND: HLX04 is a proposed biosimilar of bevacizumab. OBJECTIVE: This phase III study aimed to evaluate the efficacy, safety, and immunogenicity of HLX04 compared with reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for recurrent/metastatic colorectal cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Li, Jin, Bai, Yuxian, Shu, Yongqian, Li, Wei, Yin, Xianli, Cheng, Ying, Sun, Guoping, Deng, Yanhong, Zhong, Haijun, Li, Yunfeng, Qian, Xiaoping, Zhang, Liangming, Zhang, Jingdong, Chen, Kehe, Kang, Wenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295119/
https://www.ncbi.nlm.nih.gov/pubmed/34014555
http://dx.doi.org/10.1007/s40259-021-00484-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295119/
https://www.ncbi.nlm.nih.gov/pubmed/34014555
http://dx.doi.org/10.1007/s40259-021-00484-9

Ejemplares similares